Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and buparlisib

sorafenib has been researched along with buparlisib in 3 studies

Compound Research Comparison

Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010)
(sorafenib)		Studies
(buparlisib)		Trials
(buparlisib)		Recent Studies (post-2010) (buparlisib)
6,5207305,25125648252

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)buparlisib (IC50)
Chain A, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoformHomo sapiens (human)0.262
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformRattus norvegicus (Norway rat)0.117
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)0.1363
Cytochrome P450 1A2Homo sapiens (human)0.011
Cytochrome P450 3A4Homo sapiens (human)0.027
Cytochrome P450 2C8Homo sapiens (human)0.04
Cytochrome P450 2B6Homo sapiens (human)0.011
Phosphatidylinositol 3-kinase regulatory subunit alphaHomo sapiens (human)0.0878
Cytochrome P450 2C19Homo sapiens (human)0.372
Aldo-keto reductase family 1 member C3Homo sapiens (human)8.7
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)0.055
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)0.2507
Serine/threonine-protein kinase mTORHomo sapiens (human)1.9814
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)0.5654
DNA-dependent protein kinase catalytic subunitHomo sapiens (human)6.917
Phosphatidylinositol 3-kinase catalytic subunit type 3Homo sapiens (human)2.4905
Phosphoinositide 3-kinase regulatory subunit 5Homo sapiens (human)0.129
Serine/threonine-protein kinase mTOR Mus musculus (house mouse)0.832
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformRattus norvegicus (Norway rat)0.523

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
de Gramont, A; Dos Santos, C; Faivre, S; Raymond, E; Riveiro, ME; Serova, M; Slimane, K; Tijeras-Raballand, A1

Other Studies

3 other study(ies) available for sorafenib and buparlisib

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:5

    Topics: Aminopyridines; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Everolimus; Humans; Imidazoles; Indoles; Kidney Neoplasms; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases

2013